thalidomide has been researched along with Cell Transformation, Neoplastic in 11 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Cell Transformation, Neoplastic: Cell changes manifested by escape from control mechanisms, increased growth potential, alterations in the cell surface, karyotypic abnormalities, morphological and biochemical deviations from the norm, and other attributes conferring the ability to invade, metastasize, and kill.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Lenalidomide was not associated with AML transformation in the cohort analysis (HR = 0." | 5.43 | Subsequent primary malignancies and acute myelogenous leukemia transformation among myelodysplastic syndrome patients treated with or without lenalidomide. ( Al Ali, NH; Dalton, W; Fisher, K; Fulp, W; Hampras, SS; Kenvin, L; Knight, R; Komrokji, RS; Lancet, J; Lee, JH; List, A; Olesnyckyj, M; Padron, E; Rollison, DE; Shain, KH; Xu, Q, 2016) |
| "We report the cases of 3 patients with hematological malignancies and complex karyotypes involving der(5; 17) (p10;q10), which results in the loss of 5q and 17p." | 2.50 | der(5;17)(p10;q10) is a recurrent but rare whole-arm translocation in patients with hematological neoplasms: a report of three cases. ( Aoyama, Y; Furukawa, Y; Harada, N; Kumura, T; Manabe, M; Mugitani, A; Ohta, T; Okita, J; Tarakuwa, T, 2014) |
| "Lenalidomide was not associated with AML transformation in the cohort analysis (HR = 0." | 1.43 | Subsequent primary malignancies and acute myelogenous leukemia transformation among myelodysplastic syndrome patients treated with or without lenalidomide. ( Al Ali, NH; Dalton, W; Fisher, K; Fulp, W; Hampras, SS; Kenvin, L; Knight, R; Komrokji, RS; Lancet, J; Lee, JH; List, A; Olesnyckyj, M; Padron, E; Rollison, DE; Shain, KH; Xu, Q, 2016) |
| "Primary myelofibrosis is a clonal disease of chronic myeloproliferative neoplasm, and is a progressive clinical course with short median survival of less than 5 years after diagnosis." | 1.40 | Thalidomide treatment in a myelofibrosis patient with leukemia transformation. ( Chu, SC; Huang, WH; Kao, RH; Li, MS; Wang, TF; Wu, YF, 2014) |
| "Thalidomide has been shown to have anti-angiogenic effects in pre-clinical models as well as a significant antitumor effect in hematologic tumors." | 1.35 | Effects of thalidomide on DMBA-induced oral carcinogenesis in hamster with respect to angiogenesis. ( Ge, JP; Yang, Y; Zhou, ZT, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (9.09) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (18.18) | 29.6817 |
| 2010's | 8 (72.73) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Moros, A | 1 |
| Bustany, S | 1 |
| Cahu, J | 1 |
| Saborit-Villarroya, I | 1 |
| Martínez, A | 1 |
| Colomer, D | 1 |
| Sola, B | 1 |
| Roué, G | 1 |
| Huang, WH | 1 |
| Li, MS | 1 |
| Chu, SC | 1 |
| Wang, TF | 1 |
| Kao, RH | 1 |
| Wu, YF | 1 |
| Manabe, M | 1 |
| Okita, J | 1 |
| Tarakuwa, T | 1 |
| Harada, N | 1 |
| Aoyama, Y | 1 |
| Kumura, T | 1 |
| Ohta, T | 1 |
| Furukawa, Y | 1 |
| Mugitani, A | 1 |
| Schleiffenbaum, BE | 1 |
| Rollison, DE | 1 |
| Shain, KH | 1 |
| Lee, JH | 1 |
| Hampras, SS | 1 |
| Fulp, W | 1 |
| Fisher, K | 1 |
| Al Ali, NH | 1 |
| Padron, E | 1 |
| Lancet, J | 1 |
| Xu, Q | 1 |
| Olesnyckyj, M | 1 |
| Kenvin, L | 1 |
| Knight, R | 1 |
| Dalton, W | 1 |
| List, A | 1 |
| Komrokji, RS | 1 |
| Yang, Y | 1 |
| Ge, JP | 1 |
| Zhou, ZT | 1 |
| Breccia, M | 1 |
| Cannella, L | 1 |
| Latagliata, R | 1 |
| Nanni, M | 1 |
| Santopietro, M | 1 |
| Loglisci, G | 1 |
| Ferretti, A | 1 |
| Barzotti, R | 1 |
| Oliva, EN | 1 |
| Alimena, G | 1 |
| Geyer, JT | 1 |
| Verma, S | 1 |
| Mathew, S | 1 |
| Wang, YL | 1 |
| Racchumi, J | 1 |
| Espinal-Witter, R | 1 |
| Subramaniyam, S | 1 |
| Knowles, DM | 1 |
| Orazi, A | 1 |
| Santini, V | 1 |
| Mohla, S | 1 |
| Weilbacher, KN | 1 |
| Cher, ML | 1 |
| Oyajobi, BO | 1 |
| Poznak, CV | 1 |
| Clohisy, DR | 1 |
| Miura, M | 1 |
| Southam, CM | 1 |
| Wuest, H | 1 |
2 reviews available for thalidomide and Cell Transformation, Neoplastic
| Article | Year |
|---|---|
der(5;17)(p10;q10) is a recurrent but rare whole-arm translocation in patients with hematological neoplasms: a report of three cases.
Topics: Aged; Aged, 80 and over; Anemia, Refractory, with Excess of Blasts; Aneuploidy; Antineoplastic Combi | 2014 |
Novel therapeutic strategies: hypomethylating agents and beyond.
Topics: Aged; Aged, 80 and over; Algorithms; Cell Transformation, Neoplastic; Comorbidity; Cytogenetics; DNA | 2012 |
9 other studies available for thalidomide and Cell Transformation, Neoplastic
| Article | Year |
|---|---|
Antitumoral activity of lenalidomide in in vitro and in vivo models of mantle cell lymphoma involves the destabilization of cyclin D1/p27KIP1 complexes.
Topics: Aged; Aged, 80 and over; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Transformation, Neop | 2014 |
Thalidomide treatment in a myelofibrosis patient with leukemia transformation.
Topics: Adult; Angiogenesis Inhibitors; Bone Marrow; Cell Transformation, Neoplastic; Drug Resistance, Neopl | 2014 |
[CME myelodysplasia - a frequent hematologic neoplasia in the elderly].
Topics: Aged, 80 and over; Anemia, Aplastic; Azacitidine; Bone Marrow; Bone Marrow Examination; Cell Prolife | 2014 |
Subsequent primary malignancies and acute myelogenous leukemia transformation among myelodysplastic syndrome patients treated with or without lenalidomide.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Case-Control Studies; Cell Transformation, Neo | 2016 |
Effects of thalidomide on DMBA-induced oral carcinogenesis in hamster with respect to angiogenesis.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Angiogenesis Inhibitors; Animals; Anticarcinogenic Agents; Carcino | 2009 |
Sudden acute leukemia transformation in a MDS patient with del(5q) in complete cytogenetic remission after lenalidomide.
Topics: Acute Disease; Aged; Antineoplastic Agents; Cell Transformation, Neoplastic; Chromosome Deletion; Ch | 2011 |
Bone marrow morphology predicts additional chromosomal abnormalities in patients with myelodysplastic syndrome with del(5q).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bone Marrow; Cell Transformation, Neoplastic; | 2013 |
Third North American Symposium on Skeletal Complications of Malignancy: summary of the scientific sessions.
Topics: Animals; Bone Marrow; Bone Neoplasms; Breast Neoplasms; Cell Transformation, Neoplastic; Clinical Tr | 2003 |
Potentiating effect of thalidomide on methylcholanthrene oncogenesis in mice.
Topics: Animals; Antibody Formation; Cell Count; Cell Transformation, Neoplastic; Drug Synergism; Female; He | 1970 |